| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:351-356.)
© 2004 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Internal Medicine, National Cardiovascular Center, Osaka (N. Nagaya, S.K., H.O., N. Nakanishi, K.M.); the Cardiovascular Division, Kansai Rosai Hospital, Hyogo (M.U.); the Department of Pharmacy, National Cardiovascular Center, Osaka (K.U.); the Department of Cardiac Physiology, National Cardiovascular Center Research Institute, Osaka (M.S., H.M.); and the Department of Biochemistry, National Cardiovascular Center Research Institute, Osaka (K.K.), Japan.
Correspondence to Noritoshi Nagaya, MD, Department of Internal Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan. E-mail nagayann{at}hsp.ncvc.go.jp
Received February 3, 2003; de novo received July 28, 2003; revision received October 15, 2003; accepted October 19, 2003.
Background Adrenomedullin (AM) is a potent pulmonary vasodilator peptide. However, whether intratracheal delivery of aerosolized AM has beneficial effects in patients with idiopathic pulmonary arterial hypertension remains unknown. Accordingly, we investigated the effects of AM inhalation on pulmonary hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.
Methods and Results Acute hemodynamic responses to inhalation of aerosolized AM (10 µg/kg body wt) were examined in 11 patients with idiopathic pulmonary arterial hypertension during cardiac catheterization. Cardiopulmonary exercise testing was performed immediately after inhalation of aerosolized AM or placebo. The work rate was increased by 15 W/min until the symptom-limited maximum, with breath-by-breath gas analysis. Inhalation of AM produced a 13% decrease in mean pulmonary arterial pressure (54±3 to 47±3 mm Hg, P<0.05) and a 22% decrease in pulmonary vascular resistance (12.6±1.5 to 9.8±1.3 Wood units, P<0.05). However, neither systemic arterial pressure nor heart rate was altered. Inhalation of AM significantly increased peak oxygen consumption during exercise (peak
O2, 14.6±0.6 to 15.7±0.6 mL · kg-1 · min-1, P<0.05) and the ratio of change in oxygen uptake to that in work rate (
O2/
W ratio, 6.3±0.4 to 7.0±0.5 mL · min-1 · W-1, P<0.05). These parameters remained unchanged during placebo inhalation.
Conclusions Inhalation of AM may have beneficial effects on pulmonary hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.
Key Words: peptides hypertension, pulmonary respiration exercise hemodynamics
This article has been cited by other articles:
![]() |
D. Jin, K. Harada, S. Ohnishi, K. Yamahara, K. Kangawa, and N. Nagaya Adrenomedullin induces lymphangiogenesis and ameliorates secondary lymphoedema Cardiovasc Res, December 1, 2008; 80(3): 339 - 345. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert Review: Therapeutic advances in pulmonary arterial hypertension Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265. [Abstract] [PDF] |
||||
![]() |
A. Geambasu and T. L. Krukoff Adrenomedullin acts in the lateral parabrachial nucleus to increase arterial blood pressure through mechanisms mediated by glutamate and nitric oxide Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R38 - R44. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ertmer, A. Morelli, S. Rehberg, M. Lange, C. Hucklenbruch, H. Van Aken, M. Booke, and M. Westphal Exogenous adrenomedullin prevents and reverses hypodynamic circulation and pulmonary hypertension in ovine endotoxaemia Br. J. Anaesth., December 1, 2007; 99(6): 830 - 836. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Itoh, H. Obata, S. Murakami, K. Hamada, K. Kangawa, H. Kimura, and N. Nagaya Adrenomedullin ameliorates lipopolysaccharide-induced acute lung injury in rats Am J Physiol Lung Cell Mol Physiol, August 1, 2007; 293(2): L446 - L452. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Said Mediators and modulators of pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kato, T. Tsuruda, T. Kita, K. Kitamura, and T. Eto Adrenomedullin: A Protective Factor for Blood Vessels Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2480 - 2487. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Provencher, X. Jais, A. Yaici, O. Sitbon, M. Humbert, and G. Simonneau Clinical Challenges in Pulmonary Hypertension: Roger S. Mitchell Lecture Chest, December 1, 2005; 128(6_suppl): 622S - 628S. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nagaya, H. Mori, S. Murakami, K. Kangawa, and S. Kitamura Adrenomedullin: angiogenesis and gene therapy Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1432 - R1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nagaoka, K. A. Fagan, S. A. Gebb, K. G. Morris, T. Suzuki, H. Shimokawa, I. F. McMurtry, and M. Oka Inhaled Rho Kinase Inhibitors Are Potent and Selective Vasodilators in Rat Pulmonary Hypertension Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 494 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fujii, N. Nagaya, T. Iwase, S. Murakami, Y. Miyahara, K. Nishigami, H. Ishibashi-Ueda, M. Shirai, T. Itoh, K. Ishino, et al. Adrenomedullin enhances therapeutic potency of bone marrow transplantation for myocardial infarction in rats Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1444 - H1450. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Lowson Alternatives to nitric oxide Br. Med. Bull., November 5, 2004; 70(1): 119 - 131. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Westphal, M. Booke, and A.T. Dinh-Xuan Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension Eur. Respir. J., October 1, 2004; 24(4): 518 - 520. [Full Text] [PDF] |
||||
![]() |
D. J. Stewart, Y. D. Zhao, D. W. Courtman, N. Nagaya, T. Horio, K. Miyatake, Y. Chiba, K. Kangawa, M. Kanda, J. Hino, et al. Cell Therapy for Pulmonary Hypertension: What Is the True Potential of Endothelial Progenitor Cells? * Response Circulation, March 30, 2004; 109(12): e172 - e173. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |